CLEARWATER, Fla., April 3, 2006 (PRIMEZONE) -- Maui General Stores Inc. dba Trinity BioGenics Corp. (OTCBB:MAUG), a research and development company focused on making Adult Stem Cell procedures commercially available in conjunction with Immune Therapy, is pleased to announce that it has acquired intellectual property and laboratory assets formerly owned by Patho Biotech. This acquisition is key to the Company's future development of commercial therapeutic & diagnostic products based on the identification of nano-bacteria.
The Company's lab is operated by Dr. Luther Lindner, M.D. Dr. Lindner is a physician (pathologist) on the faculty of Texas A&M University -- College of Medicine. He is studying human blood bacterium, believed to be associated with chronic fatigue and immune dysfunction syndrome (CFIDS), fibromyalgia, and several autoimmune disorders including multiple sclerosis, lupus erythematosis, and rheumatoid arthritis.
Trinity BioGenics will use this facility to establish a research and processing laboratory to create commercial products only available via the Company’s license agreement for use nationally and abroad.
Trinity BioGenics CEO, Lawrence Stowe, stated, "The acquisition of this laboratory marks an important moment in the history of Trinity BioGenics. With the potential of our newest facility we will be able to further develop our research capability, which is our primary objective at this moment in time."
For all future Trinity BioGenics investor relations needs, investors are asked to visit the Trinity BioGenics IR Hub at http://www.agoracom.com/IR/TrinityBioGenics where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors. Alternatively, investors are able to e-mail all questions and correspondence to MAUG@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.
About Trinity BioGenics Corp.
Trinity BioGenics Corp works exclusively within the Adult Stem Cell and Biological Medicine areas. The Company's proprietary protocols are advanced, and use specific processes to obtain desired results. The FDA classifies the Company's process as a unique blood product; therefore, it will be specific and unique to Trinity BioGenics Corp. Additionally, the Company's unique combination of Immune Therapy and Adult Stem Cell treatments are like no other treatment experienced. The Company's Adult Stem Cell protocol is under preparation for Human Clinical Studies.
The statements made in this press release, which are not historical facts, contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.